Compare Patterson-UTI Energy Inc. Common Stock (PTEN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Patterson-UTI Energy Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Patterson-UTI Energy Inc. Common Stock trades at $11.6 (market cap $4.39B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Patterson-UTI Energy Inc. Common Stock pays a 3.48% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Patterson-UTI Energy Inc. Common Stock for 3 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PTEN | SYRE | |
|---|---|---|
Market Cap | $4.39B | $7.52B |
Volume | 4,811,496 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $13.15 | $108.92 |
52-Week Low | $5.41 | $22.18 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $5.47B | $6.52B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Patterson-UTI Energy (PTEN) trades at $11.52, up 1.68% today, with a neutral technical signal. The stock shows strong cash flow from operations at $961.22M for 2025, but net income remains negative at -$93.64M. Recent earnings beats and an upcoming Q3 2026 report on October 29, 2026, highlight operational momentum, supported by an average of 103 drilling rigs in September 2026. Analyst consensus is bullish with a $13.38 price target, indicating a 16% upside.
The outlook is cautiously optimistic due to earnings consistency and positive analyst sentiment, but risks include persistent net losses, exposure to oil price volatility, and competitive pressures. Upside potential hinges on sustained rig demand and profitability improvements, while downside risks stem from macroeconomic headwinds affecting energy sectors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Patterson-UTI Energy Inc. Common Stock
Patterson-UTI Energy provides drilling, completion, and other oilfield services for oil and gas producers in the United States.
Read more on PTEN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
